Baird Cuts Price Target on Regeneron (REGN) to $505; Reiterates Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to Baird Cuts Price Target on Regeneron (REGN) to $505; Reiterates Outperform
May 6, 2016 9:08 AM EDT
Leerink Partners reiterated an Outperform rating on Regeneron Pharma (NASDAQ: REGN), and raised the price target to $530.00 (from $523.00), following the company's 1Q earnings report. Total revenue beat consensus by 2% driven by higher collaboration revenue, and revenue grew by 38% compared to Q1 2015 and by 9% QoQ. The companys earnings fell short of consensus based on higher than expected SG&A and taxes. Pro forma EPS was $2.57 below consensus of $2.68.
Analyst Geoffrey Porges... More
May 5, 2016 6:36 AM EDT
Regeneron (NASDAQ: REGN) reported Q1 EPS of $2.57, $0.01 worse than the analyst estimate of $2.58. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.18 billion.
"The year is off to a very productive start at Regeneron. This quarter, we saw continued strong sales growth with EYLEA, made additional... More
May 4, 2016 2:39 PM EDT
The Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EDT
Initial Claims - Street sees 259k
Earnings:
3D Systems (NYSE: DDD) - consensus EPS $0.05
AAC Holdings (NYSE: AAC) - consensus EPS $0.15
ACI Worldwide, Inc. (Nasdaq: ACIW) - consensus loss $0.08
Agios Pharma (Nasdaq: AGIO) - consensus loss $0.79
Alibaba (NYSE: BABA) - consensus EPS... More
May 4, 2016 10:39 AM EDT
PARIS (Reuters) - Sanofi sees a strong strategic fit with Medivation (NASDAQ: MDVN) even though its tie-up proposal was rejected by the U.S. cancer drug maker last week, the company's chief executive said on Wednesday.
The French drugmaker went public with a $9.3 billion proposal to buy Medivation on April 28 but the target said offer undervalued the company and its pipeline of drugs.
...
More
May 3, 2016 10:24 AM EDT
By Laila Kearney
NEW YORK (Reuters) - U.S. pharmaceutical companies dominated an annual global ranking of top 10 large-cap stocks with the best five-year returns, according to an analysis released on Tuesday by Boston Consulting Group.
Drug company Regeneron Pharmaceuticals (NASDAQ: REGN), which had an average annual total share return of 75.3 percent, was the top performer. Allergan (NYSE: AGN) and Gilead Sciences (NASDAQ: GILD), with 43.3 percent and 41.4 percent average annual returns, respectively, took second and third... More
